Abcam, ab249235, Anti-AP-A antibody [EPR9411(2)] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal AP-A antibody. Carrier free. Suitable for IHC-P, WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR9411(2),
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IHC-P, WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab249235 is the carrier-free version of
ab155991
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
AP-A also known as Aminopeptidase A is an enzyme that plays a critical role in cellular processes by cleaving N-terminal amino acids from peptide substrates. It has a molecular mass of approximately 100 kDa. AP-A is highly expressed in the brain particularly in the hippocampus and glial cells as well as in other tissues like the kidney and placenta. Its activity has been observed in the synaptic membranes signifying its importance in neurobiological functions.
Biological function summary
Aminopeptidase A participates in the regulation of neuropeptides and peptide hormones. It forms part of the renin-angiotensin system where it influences blood pressure and fluid balance. By converting angiotensin II to angiotensin III AP-A modulates these physiological processes. Moreover it is involved in degrading enkephalins which impacts pain perception and emotional responses. This enzyme interacts with other aminopeptidases in the body contributing to various cellular functions.
Pathways
AP-A significantly impacts the renin-angiotensin system and the endothelin pathway. It influences the cardiovascular system by processing angiotensin peptides working closely with proteins such as angiotensin-converting enzyme (ACE). In the endothelin pathway AP-A affects peptide regulation and is associated with the activity of endothelin-converting enzyme. These pathways demonstrate the enzyme's role in cardiovascular health and homeostasis.
Aminopeptidase A is linked to hypertension and neurological disorders like Alzheimer's disease. Increased activity or expression of AP-A is often seen in the context of high blood pressure where it works in conjunction with ACE to modulate blood pressure levels. In Alzheimer's disease altered AP-A activity affects neuropeptide regulation linking it to beta-amyloid accumulation. These associations highlight the enzyme's potential as a target for therapeutic interventions in hypertension and neurodegenerative diseases.